Thank you, Elisabeth. So we are on a transformational journey. What you're seeing today is not a reaction to a challenging quarter. It's the result of a strategy that we deliberately set in motion already in 2024. That strategy was about taking control of our own destiny.
We recognized early that the traditional sleep app category was maturing, and that relying solely on App Store dynamics would eventually limit our growth potential.
In 2025, our focus was therefore on maintaining strong profitability, protecting cash generation, and proving that we could operate very efficiently, even in a softer market. At the same time, we laid the foundations for what comes next in 2026. We're deliberately stepping into a more investment-heavy phase because we see clear opportunities to build a larger, more diversified, and more resilient business over time. We do these investments from a position of strength.
So our transformation is about moving from one product to three. First, the Sleep Cycle app remains the number one sleep app and a profitable consumer business. Secondly, the Sleep SDK, powered by Sleep Cycle, allows us to license our proprietary technology as a horizontal layer across other products and services. And thirdly, Sleep Apnea Screening represents a long-term MedTech opportunity built on the same core technology.
Together, these form a scalable platform.
So to summarize how this fits together, all of this is part of the long-term strategy we already laid out back in 2024. At that point, we were very clear about the three focus areas. User acquisition, user engagement, and platform and data. On the left, you see the strategic building blocks: first, user acquisition and engagement through the number one Sleep Cycle app.
That has been our priority over the past two years, and it's allowed us to defend and even take market shares in the softening category.
But we also said from the beginning that the app alone would not be enough in the long run.
That's where platform and data come in. The same technology that powers the consumer app is now being reused across multiple products. In the middle. You see how this translates into concrete products. The Sleep Cycle app remains central, operating as both B2C and B2B. Sleep SDK is a pure B2B, SaaS-based offering where partners integrate our technology into their own ecosystem, and Sleep Apnea Screening is a potential product under development, addressing a large medical market using the same underlying platform.
So, on the right, you can see how this naturally leads to different business models without having to reinvent the technology each time.
So this is not a pivot.
This is about execution.
We're doing exactly what we said we would do: strengthen the app, leverage the platform, and create new scalable revenue streams on top of it. So let's unpack each of these products. The Sleep Cycle app continues to be central to us. It is profitable, it generates strong cash flows, and it gives us access to millions of engaged users across the globe. And renewal rates remain stable, which is critical in a subscription business. And we're actively working with price to mitigate the strong FX headwinds that we've had.
But just as importantly, the app generates high-quality sleep data at scale. It provides a good marketing vehicle for our tech licensing and also future sleep apnea products.
During the quarter, we launched Luma, our AI-based sleep coach, and continued development of the new Sleep Quality Score. These are not just feature updates, they are steps towards making the app more intelligent, also more personalized and better prepared for deeper and platform agnostic AI integrations going forward. This is what we mean when we say platform readiness. The consumer app is not standing still. It's evolving to support the broader strategy.
Secondly, Sleep SDK. It's a very important example of how the business model is evolving. Powered by Sleep Cycle represents a structural shift from pure consumer subscriptions to recurring B2B revenue paid by partners rather than end users. These models come with lower customer acquisition costs and also a distribution beyond the app stores, while reusing the same core technology across multiple use cases. And this is not a vision any longer. It's reality.
We launched the SDK in September. In Q4, we had already signed one pilot contract with Ultra Human, as well as a contract for a smart home manufacturer that we will disclose later this year. I'm very happy that the team managed to close these deals already in Q4, since we know that there are longer lead times in B2B. Importantly, revenue recognition follows implementation and rollout, not contract signing. That means that the commercial activity and also the cost comes first while reported revenue ramps over time.
So let's talk about Sleep Apnea Screening. It represents a significant long-term MedTech opportunity for us, both for B2B and B2C. Sleep apnea is a large and underdiagnosed global health problem, and the current pathways to finding out that you have it are often both costly, inconvenient, and slow. So our ambition is to offer a scalable and accessible screening solution using only an iPhone without the need for dedicated hardware.
This would position us as a first step in the clinical journey, as we're nearing completion of the development phase right now. And based on the results so far, I have strong confidence in the technology.
Now we're entering the validation phase with a US-based clinical partner. And this is expected to be completed in September this year. The US is our largest market.
It accounts for approximately 35% of the revenue. Conducting the validation phase in the US strengthens both the clinical evidence and is also expected to be important in future partner and B2B discussions, as well as the regulatory dialogues.
This is a key milestone toward FDA submission and future commercialization.
So to me, sleep apnea is a long-term opportunity with very meaningful potential, and we're approaching it with a level of both rigor and process that is required in MedTech. So 2025 was the year we initiated the transformation.
We protected profitability in a weaker market. We took market shares. We saw strong growth in partnerships. And we took the decision to go for medical grade Sleep Apnea Screening.
So when we look at 2026, it will be about unlocking the growth opportunities that we see, using our strong cash position to capture these opportunities. Lower margin is a conscious choice. It's about taking control of our future growth trajectory. We plan the total investments of approximately 90 million, with around 50 million impacting the PNL and 40 million being capitalized. I think it's important to notice that we invest from a position of strength. Our long-term targets are unchanged.
Revenue in 2026 is expected to come in slightly lower than in 2025, following the logic that I shared before about revenue for the new areas ramping up over time. We are expecting to return to growth in 2027 with a margin around 25%. So before we move to Q&A, let me just summarize.
First, we have a strong and profitable consumer business. It continues to generate cash even in a softer sleep app market.
Secondly, we have a clear and well-defined investment plan for 2026.
We are deliberately prioritizing our long term value creation over short term optimization.
And thirdly, we're building a scalable platform with multiple growth engines. This will make Sleep Cycle more diversified and more resilient over time. And with that, we're happy to take your questions.